HLA-E and its soluble form as indicators of a sex-specific immune response in patients with rral squamous cell carcinoma

• Verfasst von: Radermacher, Anne [VerfasserIn]
• Verfasst von: Fehrenz, Michael [VerfasserIn]
• Verfasst von: Bellin, Tamara [VerfasserIn]
• Verfasst von: Claßen, Carolina [VerfasserIn]
• Verfasst von: Möllers, Laura Christin [VerfasserIn]
• Verfasst von: Struckmeier, Ann-Kristin [VerfasserIn]
• Verfasst von: Wagner, Mathias [VerfasserIn]
• Verfasst von: Wartenberg, Philipp [VerfasserIn]
• Verfasst von: Moratin, Julius [VerfasserIn]
• Verfasst von: Freudlsperger, Christian [VerfasserIn]
• Verfasst von: Freier, Kolja [VerfasserIn]
• Verfasst von: Horn, Dominik [VerfasserIn]
• Titel: HLA-E and its soluble form as indicators of a sex-specific immune response in patients with rral squamous cell carcinoma
• Verf.angabe: Anne Radermacher, Michael Fehrenz, Tamara Bellin, Carolina Claßen, Laura Möller, Ann-Kristin Struckmeier, Mathias Wagner, Philipp Wartenberg, Julius Moratin, Christian Freudlsperger, Kolja Freier and Dominik Horn
• E-Jahr: 2023
• Jahr: 24 November 2023
• Umfang: 13 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 24.01.2024
• Weitere Titel: Titel des special issue: Oral Squamous Cell Carcinoma—Pathogenetic, Diagnostic and Therapeutic Perspectives
• Titel Quelle: Enthalten in: International journal of molecular sciences
• Ort Quelle: Basel : Molecular Diversity Preservation International, 2000
• Jahr Quelle: 2023
• Band/Heft Quelle: 24(2023), 23, special issue, Artikel-ID 16699, Seite 1-13
• ISSN Quelle: 1422-0067
• ISSN Quelle: 1661-6596
• DOI: doi:10.3390/ijms242316699
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: HLA-E
• Sach-SW: immunotherapy
• Sach-SW: oral squamous cell carcinoma (OSCC)
• Sach-SW: sex-related differences in immune response
• Sach-SW: soluble HLA-E
• K10plus-PPN: 187883696X

Abstract

The human leukocyte antigene E (HLA-E) is associated with tumorigenesis in various cancers. Immunoncology along with sex-specific aspects in cancer therapy are now in scientific focus. Therefore, immunohistochemical HLA-E expression was retrospectively analysed in a cohort of oral squamous cell carcinomas (OSCC) after surgical therapy. Then, serum concentration of HLA-E (sHLA-E) was quantified in a prospective cohort by enzyme-linked immunosorbent assay. High HLA-E expression was associated with advanced UICC stage (Spearman’s correlation: p = 0.002) and worse survival (Cox-regression: progression-free survival: hazard ratio (HR) 3.129, confidence range (CI) 1.443-6.787, p = 0.004; overall survival: HR 2.328, CI 1.071-5.060, p = 0.033). The sHLA-E concentration was significantly higher in the control group than in tumor group (Mann-Whitney U-test (MW-U): p = 0.021). Within the tumor group, women showed significantly higher sHLA-E levels than men (MW-U: p = 0.049). A closer look at the tumor group and the control group showed that gender-specific differences exist: while no differences in sHLA-E concentration were detectable between female subjects of tumor group and control group (MW-U: p = 0.916), male subjects of tumor group had a significantly lower sHLA-E concentration compared to those of control group (MW-U: p = 0.001). In summary, our results provide evidence for sex-specific differences in immune responses in OSCC. This fact should be considered regarding future immunotherapy regimens.